Abstract:Cytochrome P450 enzymes (P450s) are important in drug metabolism and have been linked to adverse drug reactions. P450s display broad substrate reactivity, and prediction of metabolites is complex. QM/MM studies of P450 reactivity have provided insight into important details of the reaction mechanisms and have the potential to make predictions of metabolite formation. Here we present a comprehensive study of the oxidation of three widely used pharmaceutical compounds (S-ibuprofen, diclofenac, and S-warfarin) by one of the major drug-metabolizing P450 isoforms, CYP2C9. The reaction barriers to substrate oxidation by the iron-oxo species (Compound I) have been calculated at the B3LYP-D/CHARMM27 level for different possible metabolism sites for each drug, on multiple pathways. In the cases of ibuprofen and warfarin, the process with the lowest activation energy is consistent with the experimentally preferred metabolite. For diclofenac, the pathway leading to the experimentally observed metabolite is not the one with the lowest activation energy. This apparent inconsistency with experiment might be explained by the two very different binding modes involved in oxidation at the two competing positions. The carboxylate of diclofenac interacts strongly with the CYP2C9 Arg108 side chain in the transition state for formation of the observed metabolite-but not in that for the competing pathway. We compare reaction barriers calculated both in the presence and in the absence of the protein and observe a marked improvement in selectivity prediction ability upon inclusion of the protein for all of the substrates studied. The barriers calculated with the protein are generally higher than those calculated in the gas phase. This suggests that active-site residues surrounding the substrate play an important role in controlling selectivity in CYP2C9. The results show that inclusion of sampling (particularly) and dispersion effects is important in making accurate predictions of drug metabolism selectivity of P450s using QM/MM methods.

Homotropic Cooperativity of Midazolam Metabolism by Cytochrome P450 3A4: Insight from Computational Studies

Mechanism of the Homotropic Cooperativity of Midazolam Metabolism by Cytochrome P450 3A4: Insight from Computational Studies

Differences of Atomic-Level Interactions between Midazolam and Two CYP Isoforms 3A4 and 3A5

The Binding Specificity Determines the Cytochrome P450 3A4-Mediated Enantioselective Metabolism of Metconazole.

Computational Investigation of the Bisphenolic Drug Metabolism by Cytochrome P450: What Factors Favor Intramolecular Phenol Coupling

CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients

Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data

Quantum Mechanics/Molecular Mechanics Modeling of Regioselectivity of Drug Metabolism in Cytochrome P450 2C9

Study on Conformation Interconversion of 3-Alkyl-4-acetyl-3;4-dihydro-2h-1;4-benzoxazines from Dynamic NMR Experiments and Ab Initio Density Functional Calculations

Structural characterization of the homotropic cooperative binding of azamulin to human cytochrome P450 3A5

High-throughput assay to simultaneously evaluate activation of CYP3A and the direct and time-dependent inhibition of CYP3A, CYP2C9, and CYP2D6 using liquid chromatography-tandem mass spectrometry

Pi-pi Stacking Mediated Cooperative Mechanism for Human Cytochrome P450 3A4.

Value of Assessing 1‐Hydroxymidazolam in Drug‐Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A

Interactions Of Omeprazole-Based Analogues With Cytochrome P450 2c19: A Computational Study

Three-Dimensional Quantitative Structure Activity Relationship for Cyp2d6 Substrates

Molecular Dynamics Simulation Framework to Probe the Binding Hypothesis of CYP3A4 Inhibitors

CYP3A4 and CYP2C19 Genetic Polymorphisms and Zolpidem Metabolism in the Chinese Han Population: a Pilot Study.

A Negative Cooperativity Mechanism of Human CYP2E1 Inferred from Molecular Dynamics Simulations and Free Energy Calculations.

Unraveling the Ligand-Binding Sites of CYP3A4 by Molecular Dynamics Simulations with Solvent Probes

Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450

Insight into the metabolism rate of quinone analogues from molecular dynamics simulation and 3D-QSMR methods.